SPRY
ARS Pharmaceuticals, Inc.·Healthcare
8.18
0.000%(+0.00)
Market ClosedLast Updated: — ET
52W L: $6.6652W H: $18.90
SPRY NEWS
globenewswire.com
3d ago
neffy® (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
neffy offers a new delivery method for epinephrine in Canada for adults and children ( > 30 kg) living with severe allergic reactions
globenewswire.com
Mar 27
ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) Label
Children were previously required to weigh ≥33 lbs. and
defenseworld.net
Mar 16
Bamco Inc. NY Buys 1,228,532 Shares of ARS Pharmaceuticals, Inc. $SPRY
Bamco Inc. NY grew its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) by 3,071.3% in the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,268,532 shares of the company's stock after acquiring an additional 1,228,532 shares during the period. Bamco Inc. NY owned about
seekingalpha.com
Mar 11
ARS Pharmaceuticals: Neffy's Slow Launch, No Guidance For 2026 Keep Me On Sidelines
ARS Pharmaceuticals, Inc. maintains a Hold rating as neffy's commercial uptake remains slow despite FDA approval and a robust marketing push. SPRY reported 2025 revenues of $84.3m, a net loss of $171.3m, and plans to sustain high SG&A spending to accelerate U.S. market share. Management offers no 2026 revenue guidance, raising concerns about breakeven prospects and ongoing competition from established and emerging epinephrine products.
seekingalpha.com
Mar 9
ARS Pharmaceuticals, Inc. (SPRY) Q4 2025 Earnings Call Transcript
ARS Pharmaceuticals, Inc. (SPRY) Q4 2025 Earnings Call Transcript
zacks.com
Mar 9
ARS Pharmaceuticals, Inc. (SPRY) Reports Q4 Loss, Beats Revenue Estimates
ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.42 per share in line with the Zacks Consensus Estimate. This compares to earnings of $0.52 per share a year ago.
